Home / News
Mission updates
Track strategic developments and technical progress from across the Axplora network. These include corporate announcements, expert insights, expansion news and industry updates.
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
News
March 17, 2026
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site 18 February, 2026 – Axplora, a global CDMO Partner for complex small molecules and antibody-drug conjugates (ADCs), today announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France Site strengthening its ability to deliver […]
Press Release
October 08, 2025
Axplora initiates global investments exceeding €100m in 2025
Raubling, 7 October, 2025 – Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today announced that the total investments initiated across its global network in 2025 will exceed €100 million. This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its […]
Press Release
August 05, 2025
Axplora Announces €6.5 Million Investment at Vizag Site and FDA Inspection Success Across Indian Operations
5 August 2025 Axplora, a global leader in API small molecule manufacturing, today announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the successful completion of routine USFDA inspections in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of […]
Press Release
June 30, 2025
Axplora announces further €35M expansion at Farmabios to double footprint and fuel long-term growth
Axplora is proud to unveil a transformative €35 million expansion at its Farmabios site in Gropello Cairoli, Italy, reinforcing the company’s longstanding commitment to serving the evolving needs of its customers through strategic investment and innovation. This latest investment builds on the €45 million already committed over the past five years, bringing Axplora’s total recent […]
Article
June 11, 2025
Axplora Strategy Teardown: A Podcast
In a recent episode of the PharmaSource podcast, Arul Ramadurai, Chief Commercial Officer at Axplora, discusses the company’s strategic focus on high-growth therapeutic areas and its customer-driven investment philosophy. Strategic Focus on High-Growth Therapeutic Areas Axplora has positioned itself in two of the fastest-growing therapeutic areas: GLP-1 peptides and antibody-drug conjugates (ADCs). The company recently […]
Press Release
June 04, 2025
Axplora’s Chasse-sur-Rhône site successfully passes its ninth consecutive regulatory inspection
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is proud to announce that its Chasse-sur-Rhône CDMO site in France has successfully passed its latest on-site inspection by the French National Agency for Medicines and Health Products Safety (ANSM). Conducted in February 2025, the inspection confirmed the site’s full compliance with […]
Press Release
March 04, 2025
Axplora expands commercial payload production capabilities at Le Mans to strengthen its leading position in ADC Manufacturing
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial manufacturing of ADCs with the launch of a cutting-edge payload manufacturing workshop at its Le Mans site (France). This expansion, which is part of the France 2030 program, builds on Axplora’s proven commercial track […]
Press Release
February 12, 2025
Axplora announces €50 Million Investment in GLP-1 Manufacturing at Mourenx (France) Site
Raubling (Germany), 12 February 2025 – Axplora, a global leader in API small molecule and ADC manufacturing, is proud to announce a landmark €50 million investment in its Mourenx site in Southwest France, securing its position as a key player in the fight against cardiovascular and metabolic diseases. Specializing in large-scale API industrial chemistry and chromatography, this […]
Article
February 09, 2025
The Road Ahead for Small Molecule APIs in 2025
What does 2025 have in store for the Future of small molecule API development and manufacturing? The landscape for small molecule active pharmaceutical ingredients (APIs) is evolving at speed. Here, Martin Meeson, CEO of Axplora, a leading manufacturer of APIs, talks about the trends that will shape the future of drug development, manufacturing, and supply […]
Partner with us today
Clear your path to launch. Contact our technical experts to manage project complexities and secure your route to market.